Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 639

3.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

4.

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.

Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Cöster L, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N.

Ann Rheum Dis. 2009 May;68(5):648-53. doi: 10.1136/ard.2007.085852. Epub 2008 May 8.

PMID:
18467516
5.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

6.

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.

Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, Olsson H, Jacobsson LT.

Ann Rheum Dis. 2005 May;64(5):699-703. Epub 2005 Feb 4.

7.

Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.

Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC.

J Rheumatol. 2007 Apr;34(4):706-11. Epub 2007 Feb 15.

PMID:
17309133
8.

The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.

Finckh A, Dehler S, Gabay C; SCQM doctors.

Ann Rheum Dis. 2009 Jan;68(1):33-9. doi: 10.1136/ard.2007.085696. Epub 2008 Jan 29.

PMID:
18230627
9.

[Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice].

La Montagna G, Tirri R, Vitello R, Malesci D, Buono R, Mennillo G, Valentini G.

Reumatismo. 2006 Oct-Dec;58(4):261-7. Italian.

10.

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.

Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S.

Arthritis Rheum. 2006 Sep;54(9):2757-64. Erratum in: Arthritis Rheum. 2006 Oct;54(10):3134.

12.

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM.

Clin Ther. 2008 Nov;30(11):1939-55. doi: 10.1016/j.clinthera.2008.11.007. Review.

PMID:
19108784
13.
14.

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.

Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG.

Arthritis Rheum. 2007 Apr;56(4):1125-33.

15.

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

Jacobsson LT, Turesson C, Gülfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P.

J Rheumatol. 2005 Jul;32(7):1213-8.

PMID:
15996054
16.

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.

17.
18.

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.

Leombruno JP, Einarson TR, Keystone EC.

Ann Rheum Dis. 2009 Jul;68(7):1136-45. doi: 10.1136/ard.2008.091025. Epub 2008 Aug 27. Review.

PMID:
18753157
19.

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.

Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA; RADIUS Investigators.

Curr Med Res Opin. 2006 Jan;22(1):185-98.

PMID:
16393444
20.

Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.

Chakravarty EF, Michaud K, Wolfe F.

J Rheumatol. 2005 Nov;32(11):2130-5.

PMID:
16265690
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk